29-Aug-2018 | Zion Market Research
Zion Market Research has published a new report titled “Breast Cancer Liquid Biopsy Market by Biomarker (Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers) and End User (Reference Laboratories, Hospitals and Physician Laboratories, and Other End Users): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024”. According to the report, global breast cancer liquid biopsy market was valued at approximately USD 151.8 million in 2017 and is expected to generate revenue of around USD 642.9 million by end of 2024, growing at a CAGR of around 22.9% between 2018 and 2024.
Liquid biopsy assesses the presence of tumor cell-derived biomarkers such as cell-free DNA (cfDNA), circulating tumor cells, extracellular vesicles (exosomes) and their cargo, proteins, and circulating cell-free RNA (cfRNA). A liquid biopsy is simpler, noninvasive, and cost-effective diagnostic tool for cancer. Liquid biopsy uses body fluids as a sample for analysis mainly blood. The amount of circulating biomarkers varies among healthy individuals and cancer patients and thus acts as a valuable tool for both early diagnosis of cancer as well as monitoring the disease progression in advanced stages of cancer to assess heterogeneity of tumor cells. Breast cancer is the second most common malignancy worldwide and thus liquid biopsy is an extremely important tool for breast cancer diagnosis and evaluation.
Browse the full "Breast Cancer Liquid Biopsy Market by Biomarker (Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers) and End User (Reference Laboratories, Hospitals and Physician Laboratories, and Other End Users): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024" report at https://www.zionmarketresearch.com/report/breast-cancer-liquid-biopsy-market
Factors such as increasing prevalence of breast cancer among women worldwide, inclination towards noninvasive procedures, government fundings, and initiatives, increasing awareness about cancer along with rising healthcare expenditure are driving the growth of the breast cancer liquid biopsy market. Additionally, technological advancements along with continuous research and development in the field of cancer and preference for personalized medicines are impacting the growth of the market. Nevertheless, the high cost of the tests, lack of trained professional, and fewer reimbursement policies can restrict the growth of the global breast cancer liquid biopsy market.
The global breast cancer liquid biopsy market has been segmented into biomarkers, end-user, and region. The biomarker segment has been classified into cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs) and others. Others segment includes circulating biomarkers such as cell-free protein biomarkers and circulating RNA (ctRNA and cfRNA). Cell-free DNA segment holds the maximum share of the biomarker segment. End users of breast cancer liquid biopsy market are physician laboratories and hospitals, reference laboratories, and other. Other end users include research institutes, pathology laboratories, academic research centers, etc.
The global breast cancer liquid biopsy market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America based on region. Over the forecast period, North America is expected to hold a maximum share of the global breast cancer liquid market followed by Europe. The U.S. is expected to lead the market in North America. Whereas, the Asia Pacific will witness the highest growth rate during the forecast period. Moderate growth is expected in the Latin America region and the Middle East and Africa would show noticeable growth for this market during the forecast period.
Some of the key players in the breast cancer liquid biopsy market are QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Illumina, Cynvenio Biosystems, Inc., Genomic Health, Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences, Inc., Biodesix, Inc., Guardant Health, Inc., and Isogen Life Science B.V., among others.
This report segments the global breast cancer liquid biopsy market as follows:
Global Breast Cancer Liquid Biopsy Market: By Biomarker
Global Breast Cancer Liquid Biopsy Market: By End User
Global Breast Cancer Liquid Biopsy Market: By Region
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651